TY  - JOUR
T1  - Fda panel: Ban 2 popular asthma drugs
AU  - Kuehn BM
Y1  - 2009/01/28
N1  - 10.1001/jama.2008.991
JO  - JAMA
SP  - 365
EP  - 366
VL  - 301
IS  - 4
N2  - 
The panel was charged with assessing the risks and benefits of certain asthma treatments, specifically the long-acting β-agonist (LABA) drugs formoterol and salmeterol and combination products containing both a LABA and an inhaled corticosteroid (formoterol plus budesonide and salmeterol plus fluticasone). Previously, the FDA’s Office of Drug Safety and the agency’s pulmonary and allergy drug products division had made contradictory recommendations concerning LABAs.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2008.991
UR  - http://dx.doi.org/10.1001/jama.2008.991
ER  -